First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab
Dabigatran, the first novel oral anticoagulant (NOAC) with a reversal agent, heralded a paradigm shift in the treatment of nonvalvular atrial fibrillation. The potential for life-threatening hemorrhagic events with the use of NOACs has been highly debated since the effectiveness of reversal agents s...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Case Reports in Cardiology |
| Online Access: | http://dx.doi.org/10.1155/2017/6458636 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849410649058181120 |
|---|---|
| author | Steven Song Joselle Cook Clive Goulbourne Matthew Meade Louis Salciccioli Jason Lazar |
| author_facet | Steven Song Joselle Cook Clive Goulbourne Matthew Meade Louis Salciccioli Jason Lazar |
| author_sort | Steven Song |
| collection | DOAJ |
| description | Dabigatran, the first novel oral anticoagulant (NOAC) with a reversal agent, heralded a paradigm shift in the treatment of nonvalvular atrial fibrillation. The potential for life-threatening hemorrhagic events with the use of NOACs has been highly debated since the effectiveness of reversal agents such as idarucizumab is based primarily on pharmacologic data. It is known that cancer patients are at an increased risk of bleeding with anticoagulation, though specific studies demonstrating the risks or efficacy of NOACs in this population are lacking. We provide the first report of hemopericardium resulting in multiorgan failure related to dabigatran use that was successfully reversed by idarucizumab in a man with prostate cancer on chemotherapy. |
| format | Article |
| id | doaj-art-5b471382e6b84ab0a2ff9cb73e73765e |
| institution | Kabale University |
| issn | 2090-6404 2090-6412 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Cardiology |
| spelling | doaj-art-5b471382e6b84ab0a2ff9cb73e73765e2025-08-20T03:35:01ZengWileyCase Reports in Cardiology2090-64042090-64122017-01-01201710.1155/2017/64586366458636First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote IdarucizumabSteven Song0Joselle Cook1Clive Goulbourne2Matthew Meade3Louis Salciccioli4Jason Lazar5Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY 11203, USADepartment of Medicine, SUNY Downstate Medical Center, Brooklyn, NY 11203, USADepartment of Medicine, SUNY Downstate Medical Center, Brooklyn, NY 11203, USADepartment of Medicine, SUNY Downstate Medical Center, Brooklyn, NY 11203, USADivision of Cardiovascular Medicine, SUNY Downstate Medical Center, Brooklyn, NY 11203, USADivision of Cardiovascular Medicine, SUNY Downstate Medical Center, Brooklyn, NY 11203, USADabigatran, the first novel oral anticoagulant (NOAC) with a reversal agent, heralded a paradigm shift in the treatment of nonvalvular atrial fibrillation. The potential for life-threatening hemorrhagic events with the use of NOACs has been highly debated since the effectiveness of reversal agents such as idarucizumab is based primarily on pharmacologic data. It is known that cancer patients are at an increased risk of bleeding with anticoagulation, though specific studies demonstrating the risks or efficacy of NOACs in this population are lacking. We provide the first report of hemopericardium resulting in multiorgan failure related to dabigatran use that was successfully reversed by idarucizumab in a man with prostate cancer on chemotherapy.http://dx.doi.org/10.1155/2017/6458636 |
| spellingShingle | Steven Song Joselle Cook Clive Goulbourne Matthew Meade Louis Salciccioli Jason Lazar First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab Case Reports in Cardiology |
| title | First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab |
| title_full | First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab |
| title_fullStr | First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab |
| title_full_unstemmed | First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab |
| title_short | First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab |
| title_sort | first reported case of hemopericardium related to dabigatran use reversed by new antidote idarucizumab |
| url | http://dx.doi.org/10.1155/2017/6458636 |
| work_keys_str_mv | AT stevensong firstreportedcaseofhemopericardiumrelatedtodabigatranusereversedbynewantidoteidarucizumab AT josellecook firstreportedcaseofhemopericardiumrelatedtodabigatranusereversedbynewantidoteidarucizumab AT clivegoulbourne firstreportedcaseofhemopericardiumrelatedtodabigatranusereversedbynewantidoteidarucizumab AT matthewmeade firstreportedcaseofhemopericardiumrelatedtodabigatranusereversedbynewantidoteidarucizumab AT louissalciccioli firstreportedcaseofhemopericardiumrelatedtodabigatranusereversedbynewantidoteidarucizumab AT jasonlazar firstreportedcaseofhemopericardiumrelatedtodabigatranusereversedbynewantidoteidarucizumab |